CLINUVEL PHARMACEUTICALS LIMITED
https://www.clinuvel.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CLINUVEL PHARMACEUTICALS LIMITED
Clinuvel Plots Competition To Incyte In Vitiligo Space
The Australian company is steadily growing its photoprotective drug in adults with erythropoietic protoporphyria but also sees a big opportunity in the pigment loss disorder.
Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.
Long-Term Vitiligo Data Appear To Lay Opzelura Safety Concerns To Rest
Incyte’s topical JAK inhibitor carries a class-wide severe safety warning and cautions against chronic use, but 52-week results could ease the way for the potential vitiligo indication.
Incyte Taps Wide-Open Vitiligo Market With Positive Ruxolitinib Results
Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Vallaurix Pte Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice